CDC-RFA-GH21-2178: Strengthening Public Health Responses and Accelerating HIV/AIDS Program for the Sustainable Provision of Comprehensive HIV/AIDS Services in Tigray Regional State of the Federal Democratic Republic of Ethiopia under PEPFAR
Closed
This grant is closed. A newer notice from the same program is forecast: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (CDC-RFA-JG-27-0070). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - CGH notices from 2021.
Centers for Disease Control - CGH offered grants to the applicants described in the notice. It expected to make one award. Applications closed on April 22, 2021.
From the official notice on Grants.gov, last changed March 24, 2021. Checked November 7, 2026.
- Expected awards1
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 23, 2021 |
|---|---|
| Deadline | April 22, 2021 |
| Archived by Grants.gov | May 23, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants that can apply for this NOFO are:Tigray Regional Health Bureau of Ethiopia
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (60% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $5,000,000 for Year 1, subject to the availability of funds. This NOFO intends to re-establish the support to Tigray Regional Health Bureau (TRHB) in the implementation of comprehensive HIV services in the Tigray Region to attain the UNAIDS 95-95-95 goals. The Tigray region accounts for 56,863 (8%) of the people living with HIV population and 42,110 people on antiretroviral therapy (ART) in Ethiopia. With this NOFO, the TRHB will further strengthen its program management, technical, and monitoring capacity at all levels of the health system. The program will focus on geographies and populations highly affected by the HIV/AIDS pandemic to have greater impact and operational efficiency. Building on current achievements, the TRHB will focus on priority activities that have a significant impact on epidemic control of HIV/AIDS such as targeted HIV testing services (HTS), linkage to and initiation of ART, ensuring retention in treatment and ensuring HIV viral load (VL) suppression.
Who has won Global AIDS grants before
From fiscal 2021 to 2025, Global AIDS (93.067) awarded $7.6 billion across 521 grant awards, an average of $14.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 32 | $684 million |
| Elizabeth Glaser Pediatric AIDS Foundation | District of Columbia | 13 | $387 million |
| Management and Development for Health | 5 | $282 million | |
| Apin Public Health Initiatives LTD/Gte | 4 | $209 million | |
| University of Washington | Washington | 8 | $195 million |
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before
From fiscal 2021 to 2025, Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security (93.318) awarded $1.3 billion across 306 grant awards, an average of $4.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| African Field Epidemiology Network LTD | 6 | $147 million | |
| The Task Force for Global Health, Inc. | Georgia | 7 | $138 million |
| World Health Organization, Somalia | 14 | $125 million | |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 3 | $61.5 million |
| The Johns Hopkins University | Maryland | 5 | $42.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-GH21-2178 still open?
No. It closed on April 22, 2021. A newer notice is forecast: CDC-RFA-JG-27-0070, expected deadline February 12, 2027.
Who can apply for Strengthening Public Health Responses and Accelerating HIV/AIDS Program for the Sustainable Provision of Comprehensive HIV/AIDS Services in Tigray Regional State of the Federal Democratic Republic of Ethiopia under PEPFAR?
Centers for Disease Control - CGH accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Strengthening Public Health Responses and Accelerating HIV/AIDS Program for the Sustainable Provision of Comprehensive HIV/AIDS Services in Tigray Regional State of the Federal Democratic Republic of Ethiopia under PEPFAR?
Closed April 22, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Global AIDS grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, Elizabeth Glaser Pediatric AIDS Foundation, Management and Development for Health. The program made 521 awards worth $7.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)